Standout Papers

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia... 2019 2026 2021 2023 438
  1. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study (2019)
    Andrew H. Wei, Stephen A. Strickland et al. Journal of Clinical Oncology

Immediate Impact

2 from Science/Nature 66 standout
Sub-graph 1 of 21

Citing Papers

Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
2025 Standout
Cell death
2024 Standout
12 intermediate papers

Works of John Hayslip being referenced

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
2019 Standout
Correlative Biomarkers of Response to Venetoclax in Combination with Chemotherapy or Hypomethylating Agents in Elderly Untreated Patients with Acute Myeloid Leukemia
2016
and 1 more

Author Peers

Author Last Decade Papers Cites
John Hayslip 610 161 492 201 28 929
Sven‐Aage Killmann 431 127 283 210 39 846
Bertil Uggla 585 403 476 191 31 1.1k
Elisabeth Oppliger Leibundgut 403 176 477 305 38 879
S. Faderl 863 238 409 386 24 1.2k
Peter Ernst 344 199 288 113 40 807
C. Michel Zwaan 662 163 335 176 33 954
MC Cañizo 933 154 279 338 25 1.2k
Mammo Amare 360 215 238 81 28 816
Muhammad Shurafa 415 315 269 256 29 897
Mette Østergaard 408 162 382 111 29 830

All Works

Loading papers...

Rankless by CCL
2026